Pharmacodynamic effects in blood and tumor tissue of eftozanermin alfa, a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist.
Monica Motwani(AbbVie (United States)), Patricia LoRusso(Yale Cancer Center), Emiliano Calvo(South Texas Accelerated Research Therapeutics), Alexis Cunningham(AbbVie (United States)), Chun Zhang(Shantou University), Sudhir Penugonda(ClearMotion (United States)), Joann P. Palma(Abbott Fund), Maja J.A. de Jonge(Erasmus MC Cancer Institute), Dimple Modi(AbbVie (United States))
Cited by 0
Related Papers
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
|The Lancet Oncology|2012|1.3k
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
|The Lancet Oncology|2016|1.3k
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776